Core Viewpoint - Zhongsheng Pharmaceutical's innovative drug Angladewe Tablets (brand name: Anruiwei) has been included in the National Medical Insurance Directory for the first time through national medical insurance negotiations for 2025 [1] Group 1: Company Developments - The company announced that its core products, including Lai Ru Te Wei Tablets, Compound Thrombus Tong Capsules, Cerebral Thrombus Tong Capsules, Sucralfate Oral Suspension, Carboxymethyl Starch Oral Solution, and Nitazoxanide Eye Drops, have also been included in the National Medical Insurance Directory [1]

Core Viewpoint - Junshi Biosciences has announced that two of its products, Toripalimab Injection (brand name: Tuoyi®) and Engreztinib Injection (brand name: Junshida®), have been included in the National Medical Insurance Catalog (2025) under the Class B category, effective January 1, 2026 [1] Group 1: Product Developments - Toripalimab has received approval for all 12 indications in mainland China and is the only anti-PD-1 monoclonal antibody in the catalog for treating renal cancer, triple-negative breast cancer, and melanoma [1] - Engreztinib is newly included in the catalog and is the only domestic PCSK9-targeted drug for patients intolerant to statins [1] Group 2: Market Implications - The inclusion of these products in the National Medical Insurance Catalog is expected to enhance their market accessibility and potentially increase sales [1] - With four commercialized products now listed in the National Medical Insurance Catalog, the company is positioned to benefit from broader patient access and reimbursement support [1]

格隆汇12月7日｜康诺亚宣布，公司自主研发的国家1类新药康悦达®（司普奇拜单抗注射液）纳入《国 家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，该目录将自2026年1月1日起正式实施。 此次纳入新版国家基本医疗保险药品目录，康悦达®（司普奇拜单抗）在多个适应症上填补了治疗领域 空白和医保目录空白：它是国产首个治疗中重度特应性皮炎的生物制剂，带来更高治疗获益，打破了长 期以来进口药物的垄断, 为外用药控制不佳的患者带来靶向治疗新选择；同时，它也是国内首个治疗慢 性鼻窦炎伴鼻息肉的生物制剂、全球唯一治疗季节性过敏性鼻炎的IL-4Rα抗体药物，为传统治疗手段效 果不佳、存在未满足临床需求的患者提供了革新性的治疗方案。 ...

格隆汇8月22日丨德琪医药-B(06996.HK)公布中期业绩，截至2025年6月30日止六个月，收入由从截至 2024年6月30日止六个月的人民币6080万元减少人民币760万元至人民币5320万元。于2023年12月，希维 奥®(塞利尼索)成功获纳入2023年版国家医保目录，由于积极的市场预期，初始推动了截至2024年6月30 日止六个月的强劲市场增长。随后，市场需求逐渐恢复理性。值得注意的是，截至2025年6月30日止六 个月的收入较2024年下半年增加人民币2200万元，反映收入的稳步增长与稳定状况。 期内亏损从截至2024年6月30日止六个月的人民币1.670亿元减少人民币9060万元至截至2025年6月30日 止六个月的人民币7640万元。 ...

Core Viewpoint - Shanghai Yizhong is facing significant performance pressure as its second-largest shareholder, Shanghai Kaibao, plans to reduce its stake amid high stock prices and declining earnings [2][9]. Shareholder Actions - On July 16, Shanghai Kaibao announced plans to sell up to 6.2011 million shares of Shanghai Yizhong, currently holding 24.7035 million shares, representing 11.95% of the company [2][4]. - This marks the second time Shanghai Kaibao has reduced its stake, having previously sold 1.0476 million shares in 2022 for approximately 97.2716 million yuan [2][8]. - As of July 17, Shanghai Yizhong's stock price was 67.9 yuan per share, reflecting a 70% increase year-to-date, with the current market value of Shanghai Kaibao's holdings around 1.677 billion yuan [4][9]. Company Performance - Shanghai Yizhong reported a revenue of 71.0322 million yuan in Q1 2025, a year-on-year increase of 3.39%, but net profit fell by 51.38% to 14.186 million yuan [3][10]. - The company experienced a significant decline in performance in 2024, with revenues dropping to 174 million yuan, a decrease of 51.83%, and net profit down 95.68% [10]. - The core product, paclitaxel micelles, was not included in the medical insurance directory until November 2024, impacting market access and sales performance [9][10]. Financial Metrics - In 2024, Shanghai Yizhong's sales and R&D expenses were 115 million yuan and 37.2037 million yuan, respectively, reflecting increases of 8.28% and 65.71% [10]. - For Q1 2025, sales and R&D expenses were 28.2088 million yuan and 9.2766 million yuan, accounting for 39.7% and 13.06% of total revenue [10].